New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. To...
Austrian biotech company AFFiRiS AG has announced a €6 million euro (more than $8 million US dollars) grant from the European Union to continue deve...
SIGN UP FOR EMAIL UPDATES
GET PARKINSON'S RESEARCH NEWS, FOUNDATION UPDATES, INVITATIONS TO EVENTS AND MORE.